Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Translational team-up
September 2017
SHARING OPTIONS:

SEATTLE—Adaptive Biotechnologies has launched a translational collaboration with the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) with the aim of using Adaptive’s immunoSEQ Platform to increasingly include T cell and B cell receptor sequencing into NCI-sponsored clinical trials. The organizations hope to use the platform to more accurately measure and track immune repertoire dynamics that could influence patients’ response to different cancer immunotherapies.
 
“We are delighted to announce our engagement with NCI,” said Chad Robins, CEO and founder of Adaptive Biotechnologies. “It’s our goal to support NCI investigators by enriching their research and expertise in immune correlative data generation with Adaptive’s immunoSEQ Platform, and to help expedite the development of new immune molecular biomarkers that inform the next wave of novel therapies and rational combinations.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.